Octavio Marquez
CIK 1917170 · View on SEC EDGAR ↗
First SEC filing: March 16, 2022 · Latest: March 10, 2025
On this page
- Insider at Companies where this person is a reporting insider.
- Insider transactions Every share this person bought or sold, from Form 4 filings.
- Derivatives Options and other derivative holdings reported by this person.
- Initial holdings The stakes this person held when they first started reporting.
- Compensation Executive pay disclosed in company proxy statements.
Insider at
Insider transactions
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| Nov. 12, 2024 | DBD | P | 491 | $40.57 | $19,920 | 137,464 Direct | +0.36% | Acquired | 66.1% (price as of 2026-08-20) |
| Nov. 12, 2024 | DBD | P | 1,199 | $40.95 | $49,099 | 136,973 Direct | +0.88% | Acquired | 64.6% (price as of 2026-08-20) |
| Aug. 9, 2024 | DBD | P | 1,100 | $37.34 | $41,074 | 135,774 Direct | +0.82% | Acquired | 80.5% (price as of 2026-08-20) |
| May 6, 2024 | DBD | P | 235 | $38.92 | $9,146 | 134,674 Direct | +0.17% | Acquired | 73.2% (price as of 2026-08-20) |
| May 6, 2024 | DBD | P | 278 | $38.89 | $10,811 | 134,439 Direct | +0.21% | Acquired | 73.3% (price as of 2026-08-20) |
| March 14, 2024 | DBD | P | 500 | $33.80 | $16,900 | 134,161 Direct | +0.37% | Acquired | 99.4% (price as of 2026-08-20) |
| March 13, 2024 | DBD | P | 22 | $34.18 | $752 | 133,661 Direct | +0.02% | Acquired | 97.2% (price as of 2026-08-20) |
| March 13, 2024 | DBD | P | 978 | $34.27 | $33,516 | 133,639 Direct | +0.74% | Acquired | 96.6% (price as of 2026-08-20) |
| Nov. 13, 2023 | DBD | P | 1,000 | $21.50 | $21,500 | 2,100 Direct | +90.91% | Acquired | 213.4% (price as of 2026-08-20) |
| Aug. 30, 2023 | DBD | P | 1,000 | $18.69 | $18,690 | 1,100 Direct | +1000.00% | Acquired | 260.6% (price as of 2026-08-20) |
| Aug. 14, 2023 | DBD | P | 100 | $23.69 | $2,369 | 339,014 Direct | +0.03% | Acquired | 184.5% (price as of 2026-08-20) |
| Aug. 14, 2023 | DBD | P | 100 | $23.69 | $2,369 | 100 Direct | — | Acquired | 184.5% (price as of 2026-08-20) |
| Feb. 14, 2023 | DBD | P | 7,000 | $2.92 | $20,440 | 358,286 Direct | +1.99% | Acquired | 2207.9% (price as of 2026-08-20) |
| Feb. 13, 2023 | DBD | P | 20,000 | $2.26 | $45,200 | 351,286 Direct | +6.04% | Acquired | 2881.9% (price as of 2026-08-20) |
| Feb. 13, 2023 | DBD | P | 10,000 | $2.31 | $23,100 | 331,286 Direct | +3.11% | Acquired | 2817.3% (price as of 2026-08-20) |
| May 12, 2022 | DBD | P | 1,500 | $2.27 | $3,405 | 325,719 Direct | +0.46% | Acquired | 2868.7% (price as of 2026-08-20) |
| May 12, 2022 | DBD | P | 20,420 | $2.28 | $46,558 | 324,219 Direct | +6.72% | Acquired | 2855.7% (price as of 2026-08-20) |
| May 12, 2022 | DBD | P | 5,371 | $2.25 | $12,085 | 303,799 Direct | +1.80% | Acquired | 2895.1% (price as of 2026-08-20) |
| May 12, 2022 | DBD | P | 21,500 | $2.26 | $48,590 | 298,428 Direct | +7.76% | Acquired | 2881.9% (price as of 2026-08-20) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II)
Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| Jan. 19, 2024 | DBD | Employee Stock Option (right to buy) | Common Stock (250,443) | $30.90 | Jan. 19, 2034 | 250,443 | Acquired |
| Aug. 11, 2023 | DBD | Non-Qualified Stock Option [F3] | Common Shares (9,372) | $11.96 | Jan. 30, 2030 | 9,372 | Disposed |
| Aug. 11, 2023 | DBD | Non-Qualified Stock Option [F3] | Common Shares (33,843) | $4.08 | Jan. 29, 2029 | 33,843 | Disposed |
| Aug. 11, 2023 | DBD | Non-Qualified Stock Option [F3] | Common Shares (19,786) | $18.75 | Feb. 1, 2028 | 19,786 | Disposed |
| Aug. 11, 2023 | DBD | Non-Qualified Stock Option [F3] | Common Shares (37,996) | $26.60 | Feb. 8, 2027 | 37,996 | Disposed |
| Aug. 11, 2023 | DBD | Non-Qualified Stock Option [F2] | Common Shares (16,388) | $27.39 | Feb. 3, 2026 | 16,388 | Disposed |
| Aug. 11, 2023 | DBD | Non-Qualified Stock Option [F2] | Common Shares (22,735) | $32.33 | Feb. 5, 2025 | 22,735 | Disposed |
| Aug. 11, 2023 | DBD | Non-Qualified Stock Option [F2] | Common Shares (15,885) | $34.13 | Feb. 11, 2024 | 15,885 | Disposed |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Initial ownership (Form 3) 8 holdings
Securities held when first becoming an insider, per SEC Form 3.
| Date | Ticker | Security | Shares | Ownership |
|---|---|---|---|---|
| March 16, 2022 | DBD | Common Shares | 276,928 | Direct |
| March 16, 2022 | DBD | Non-Qualified Stock Option [F2]→ Common Shares (15,885) | 15,885 | Direct |
| March 16, 2022 | DBD | Non-Qualified Stock Option [F2]→ Common Shares (22,735) | 22,735 | Direct |
| March 16, 2022 | DBD | Non-Qualified Stock Option [F2]→ Common Shares (16,388) | 16,388 | Direct |
| March 16, 2022 | DBD | Non-Qualified Stock Option [F3]→ Common Shares (37,996) | 37,996 | Direct |
| March 16, 2022 | DBD | Non-Qualified Stock Option [F3]→ Common Shares (19,786) | 19,786 | Direct |
| March 16, 2022 | DBD | Non-Qualified Stock Option [F3]→ Common Shares (33,843) | 33,843 | Direct |
| March 16, 2022 | DBD | Non-Qualified Stock Option [F3]→ Common Shares (9,327) | 9,327 | Direct |
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
DBD
President and CEO| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2024 | $850,000 | — | $4,219,371 | $2,734,838 | $1,688,916 | — | $33,584 | $9,526,709 |
| 2023 | $850,000 | $500,000 | — | — | $762,987 | — | $135,426 | $2,248,413 |
| 2022 | $779,755 | — | $4,343,685 | — | — | — | $536,894 | $5,660,334 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.